TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Amplia Therapeutics ( (AU:ATX) ) has provided an announcement.
Amplia Therapeutics has announced promising results from its ACCENT clinical trial, which tests the FAK inhibitor narmafotinib in combination with chemotherapy for advanced pancreatic cancer. The trial has shown an improved Objective Response Rate of 33% compared to 23% with chemotherapy alone, and a mean duration on trial of 219 days, indicating enhanced efficacy and durability. Narmafotinib continues to demonstrate good tolerability, with no significant increase in chemotherapy-related side effects, positioning Amplia favorably in the cancer treatment landscape.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, with a focus on fibrotic cancers such as pancreatic and ovarian cancer. The company is advancing its pipeline with narmafotinib, a potent and selective FAK inhibitor, which is gaining attention for its role in solid tumors.
Average Trading Volume: 3,703,881
Technical Sentiment Signal: Buy
Current Market Cap: A$89.79M
For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.